摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-Amino-2-methoxy-phenoxy)-propanol-(2) | 100132-55-6

中文名称
——
中文别名
——
英文名称
1-(4-Amino-2-methoxy-phenoxy)-propanol-(2)
英文别名
1-(4-amino-2-methoxyphenoxy)propan-2-ol
1-(4-Amino-2-methoxy-phenoxy)-propanol-(2)化学式
CAS
100132-55-6
化学式
C10H15NO3
mdl
——
分子量
197.234
InChiKey
FYHXWZKAXFUIFB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    14
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    64.7
  • 氢给体数:
    2
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS
    申请人:Stein Philip D.
    公开号:US20090011994A1
    公开(公告)日:2009-01-08
    The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R 1 , R 2 , R 3 , R 8 , and R 9 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.
    本申请提供了根据公式I提供的化合物,包括所有立体异构体、溶剂合物、前药和药学上可接受的形式, 其中 R 1 ,R 2 ,R 3 ,R 8 和R 9 在此定义。 此外,本申请提供了含有至少一种根据公式I的化合物和可选至少一种额外治疗剂的药物组合物。最后,本申请提供了治疗患有MCHR-1调节性疾病或紊乱的患者的方法,例如肥胖症、糖尿病、抑郁症或焦虑症,通过给予根据公式I的化��物的治疗有效剂量。
  • Non-basic melanin concentrating hormone receptor-1 antagonists
    申请人:Washburn N. William
    公开号:US20070093509A1
    公开(公告)日:2007-04-26
    The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.
    本申请提供了按照公式I提供的化合物,包括所有立体异构体、溶剂合物、前药和药学上可接受的形式。此外,本申请提供了含有至少一种按照公式I的化合物和可选的至少一种额外治疗剂的制药组合物。最后,本申请提供了通过给予按照公式I的化合物的治疗有效剂量来治疗患有MCHR-1调节的疾病或疾病,例如肥胖症、糖尿病、抑郁症或焦虑症的患者的方法。
  • AZOLOPYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS
    申请人:Devasthale Pratik
    公开号:US20110195934A1
    公开(公告)日:2011-08-11
    The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable faints thereof according to wherein all of the variables are defined herein.
    本申请提供了化合物,包括所有立体异构体、溶剂化物、前药和药学上可接受的盐,其中所有变量在此定义。
  • AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS
    申请人:Devasthale Pratik
    公开号:US20110218185A1
    公开(公告)日:2011-09-08
    The present application provides compounds that are useful as MCHR1 antagonists, especially for the treatment of obesity, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein the variables are defined herein.
    本申请提供了一些化合物,它们可用作MCHR1拮抗剂,特别适用于治疗肥胖症,包括所有立体异构体、溶剂合物、前药和药学上可接受的I式形式,其中变量在此定义。
  • SUBSTITUTED PYRAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS
    申请人:Stein Philip D.
    公开号:US20110144060A1
    公开(公告)日:2011-06-16
    The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R 1 , R 2 , R 3 , R 8 , and R 9 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.
    本申请提供了一种化合物,包括所有立体异构体、溶剂化合物、前药和其制备的药学上可接受的形式,其化学式为I式,其中R1、R2、R3、R8和R9的定义如本文所述。此外,本申请还提供了含有至少一种I式化合物和可选的至少一种其他治疗剂的药物组合物。最后,本申请提供了通过给予I式化合物的治疗有效剂量来治疗患有MCHR-1调节性疾病或疾病的患者的方法,例如肥胖症、糖尿病、抑郁症或焦虑症。
查看更多